RxDoctor Payments Data

Danny Lee, MD

Clinical Cardiac Electrophysiology · Orange, CANPI 1740568427

Payments from drug & device makers

$18,603in general payments, 2019–2025

Across 321 payments — averaging $57.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Abbott$6K
  • Philips North America LLC$1K
  • Boston Scientific$910
  • AOP Health US, LLC$793
  • Biosense Webster, Inc.$615
  • plus $3K from 28 others

What the payments were for

  • Travel & lodging$7,22539%
  • Food & beverage$11,26061%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,603 in reported general payments places this provider in the 30th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$222,885
Medicare patients
501
Services billed
1,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban369$407,822
XareltoRivaroxaban34$47,515
EntrestoSacubitril/Valsartan13$14,211
Diltiazem 12hr ErDiltiazem Hcl48$8,501
Amiodarone Hcl81$3,025
Metoprolol Succinate195$2,330
Diltiazem 24hr Er (Xr)Diltiazem Hcl44$1,800
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$1,744
Flecainide Acetate65$1,660
Sotalol AfSotalol Hcl48$1,512
Diltiazem 24hr Er (La)Diltiazem Hcl11$1,336
Metoprolol Tartrate168$1,180
SotalolSotalol Hcl26$637
Carvedilol67$635
Atorvastatin Calcium14$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$407,822369 claims
Johnson & JohnsonXarelto$29$47,51534 claims
NovartisEntresto$235$14,21113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →